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Summary Single-agent therapy with paclitaxel is effective against both squamous cell carcinoma and adenocarcinoma of the oesophagus.
However, only limited data are available on the combination of paclitaxel with other cytotoxic drugs in this entity. Patients with unresectable
stage l1l, recurrent or metastatic tumours were treated in a multicentre setting with paclitaxel 90 mg m-2 given over 3 h intravenously, followed
by cisplatin 50 mg m-2. The courses were repeated every 14 days. Twenty patients with squamous cell carcinoma or adenocarcinoma of the
oesophagus were evaluable for response. The overall remission rate was 40% (8/20), including 15% (3/20) clinically complete responses.
Clinical benefit response, defined as relief of dysphagia and/or significant gain in weight, was achieved in 70% of the patients. Neutropenia of
CTC grade 3 occurred only in 10% of the patients; no grade 4 neutropenia and no severe thrombocytopenia was encountered. CTC grade 4
neurotoxicity was seen in 5% of patients. Cisplatin/paclitaxel administered every 14 days, was effective in patients with poor prognosis
oesophageal cancer and toxicity was acceptable.
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Several chemotherapeutic agents have been adequately investi-
gated in patients with oesophageal cancer, predominantly with
squamous cell histology. The most active drugs, with a response
rate of at least 20%, are bleomycin, cisplatin, 5-fluorouracil,
methotrexate, mitomycin-C and vindesine (Ajani, 1994).
Currently, the combination of 5-fluorouracil and cisplatin is
considered th6 standard treatment for squamous cell carcinoma of
the oesophagus, with 50% of the patients responding to the treat-
ment. Paclitaxel has demonstrated significant clinical activity
against a variety of tumours. After a 24-h continuous infusion
of 250 mgm-2 paclitaxel, Ajani et al (1994) achieved either a
complete or partial response in 32% of oesophageal cancer
patients.
Only limited data are available on the combination ofpaclitaxel
with other cytotoxic drugs in oesophageal cancer. Ajani et al
(1995) have reported the preliminary results of a regimen
combining paclitaxel with cisplatin and a continuous infusion of
5-fluorouracil. The overall remission rate was 44%. Gelmon and
colleagues (Gelmon et al, 1996) established the maximum toler-
ated dose of paclitaxel in combination with cisplatin, repeated
biweekly, in patients with metastatic breast cancer. The objective
of our trial was to evaluate the response rate and the toxic effects
of cisplatin/paclitaxel, repeated biweekly, in previously untreated
patients with unresectable, recurrent or metastatic carcinoma of
the oesophagus.
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PATIENTS AND METHODS
All patients who entered the trial were required to have inoperable,
recurrent or metastatic, biopsy-proven squamous cell carcinoma or
adenocarcinoma of the oesophagus with measurable disease.
Patients with locally advanced disease underwent surgical evalua-
tion, before study enrolment, to confirm unresectability.
Measurable disease was defined as bidimensionally measurable
lesions with margins clearly defined by computerized tomography
scan (CT), by magnetic resonance imaging (MRI) or by endo-
scopic ultrasound (EUS). Additional eligibility criteria were no
prior chemo- or radiotherapy, age < 75 years, performance status
WHO 0-2, white blood cell (WBC) count > 3 x 1091-1, platelet
count > 100 x 1091-', a creatinine clearance > 60 ml min-',
bilirubin levels < 1.3 mg dl-' and informed consent.
Pretreatment evaluation consisted of physical examination,
evaluation of dysphagia or pain symptoms, complete biochemical
profile, chest radiograph, CT of the thorax and abdomen, abdom-
inal sonography and endoscopical examination. MRI, bron-
choscopy, EUS and barium oesophagogram were performed when
clinically indicated. For response evaluation, CT, MRI, and in one
case EUS, were repeated every 6 weeks, and a questionnaire was
used to assess changes in swallowing, use of analgesic and pain
score. The treatment effect was evaluated by the physicians of the
cooperating centres. Furthermore, CT and MRI scans from all
patients were re-evaluated by an additional radiologist in a blinded
fashion. Median survival and median time to progression were
measured from beginning of therapy until the last follow-up, or
death.
Adverse events and therapeutic response were rated according
to WHO standard criteria, complete response (CR) was defined as
the disappearance of all known disease, determined by two obser-
vations not less than 4 weeks apart. Partial response (PR) required
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a 50% or more decrease in total tumour size of the lesions, which
had been measured to determine the effect of therapy by two
observations not less than 4 weeks apart. In addition, no appear-
ance of new lesions or progression of any lesion should be
reported. No change (NC) required a < 50% decrease or < 25%
increase in the size of the indicator lesion. Finally, progressive
disease (PD) was defined as a 25% or more increase in the size of
one or more measurable lesions, or the appearance of new lesions.
Complete remission of dysphagia was defined as complete relief
ofdysphagia (patient can eat a normal diet). Partial remission was
stated when symptoms improved from dysphagia when swal-
lowing liquids to dysphagia on soft food/intake of a regular diet
only, or from dysphagia on soft food to symptoms only on intake
of a regular diet.
The intravenous (i.v.) treatment consisted of paclitaxel 90 mg m-2
administered over a 3-h period, followed by cisplatin 50 mg m-2 over
60 min on day 1. All patients were premedicated with dexa-
methasone 20 mg, cimetidine 300 mg and clemastine 2 mg i.v.
30 min prior to the administration of paclitaxel. Adequate pre- and
posthydration was given with the infusion of cisplatin. Provided
patients had recovered from all toxic effects, courses were repeated
every 14 days until progression or unacceptable toxicity. Patients with
locally advanced disease were allowed to undergo irradiation after
cytostatic treatment, orwere referred for surgery. All patients received
ondansetron (8 mg i.v.) and dexamethasone (20 mg i.v.) before infu-
sion of cisplatin/paclitaxel as antiemetic treatment. The trial was
approved by the local ethics committee (University ofBochum).
RESULTS
Pretreatment characteristics
Twenty-four patients from seven different centres were enrolled
into this phase II trial. Median age was 57 years (range 39-72).
The majority of patients were men (male-female ratio was 20:4).
Eighteen patients had a squamous cell cancer and six patients had
an adenocarcinoma. The tumours were located in the upper
oesophagus in six patients, in the middle oesophagus in five
patients and the lower part of the oesophagus in 13 patients. On
study entry, 14 patients presented with distant metastases (UICC
stage IV); five of these 14 patients had a relapse after primary
oesophageal resection. An additional ten patients in UICC stage III
were enrolled, two of them with local recurrence. No patients had
received prior chemotherapy or irradiation.
Twenty patients were evaluable for response. Because of poor
compliance in patients abusing alcohol, restaging after
chemotherapy could not be performed in four cases. Nine ofthese
20 patients had local recurrence only or a stage III tumour. Eleven
evaluable patients had metastatic disease.
Table 1 Toxicity (% of patients)
Common toxicity criteria (CTC) grade
0 1 2 3 4
Anaemia 40 20 30 10 0
Leucopenia 40 40 10 10 0
Thrombocytopenia 85 15 0 0 0
Infection 95 0 5 0 0
Vomiting 90 0 10 0 0
Stomatitis 100 0 0 0 0
Diarrhoea 100 0 0 0 0
Alopecia 5 55 40 - -
Neurotoxicity 80 10 10 0
(sensory)
Neurotoxicity 95 0 0 0 5
(motor)
Neurotoxicity 90 5 0 5 0
(ototoxicity)
Worst toxicity scores for patients (n = 20) after chemotherapy with
cisplatin/paclitaxel (mean = 6.55 cycles per patient).
Toxicity
Toxicity scores are summarized in Table 1. In one patient, treat-
ment was discontinued because of CTC grade 3 ototoxicity (audi-
tory defect, corrected by hearing aid), and one further patient
experienced a CTC grade 4 neuropathy (paralysis of the peroneal
nerve with weakness of dorsi flexion of toes and foot). Treatment
related death was not reported.
Remission and survival
A median of6.55 cycles per patient (range 3-13) and a total of 131
cycles were administered. The overall response rate was 40%
[8/20, 95% confidence internal (CI) 0.185-0.614], including 15%
(3/20) clinically complete remissions (Table 2). No change/minor
responses were observed in 15% (3/20). Median progression-free
survival for all responders was 8 months, including one patient
with a PR who was referred to surgery after the cytostatic treat-
ment and three patients with locally advanced tumours, receiving
radiation after remission with cisplatin/paclitaxel. Progressive
disease was observed in nine patients (45%, CI 0.232-0.668). At
the time of analysis, 13 of the 20 evaluable patients who entered
into the trial had died. Median survival duration from the start of
treatment was 7.0 months; median survival time for responding
patients was 11 months.
Fifty per cent of the patients (7/14) with squamous cell cancer
responded to the polychemotherapy and 17% (1/6) of those with
adenocarcinoma.
Table 2 Results
All patients Stage IlI/local Stage IV Squamous cell Adenocarcinoma
(n = 20) recurrence (n = 9) (n = 11) cancer(n = 14) (n = 6)
CR/PR 8 (40%) 4 (44%) 4 (36%) 7 (50%) 1 (17%)
NC/MR 3 (15%) 2 (22%) 1 (9%) 1 (7%) 2 (33%)
Response in 20 evaluable patients with cancer of the oesophagus, receiving a combination chemotherapy with cisplatin/paclitaxel. Figures in parentheses show
per cent of patients.
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Results in stage Ill patients
Forty-four per cent (CI 0.120-0.770) of the patients with local
recurrence only or in UICC stage III, responded to the therapy.
There was one complete responder and three partial remissions.
One patient with PR after cisplatin/paclitaxel underwent
oesophageal resection (pRO), but presented with hepatic metastasis
7 months later. Five patients (three responders and two non-
responders) were treated with radiotherapy after the study medica-
tion. The median survival time in this group was 14 months.
Results in stage IV patients
Two PRs and two CRs were achieved in the 11 patients with UICC
stage IV disease (remission rate 36%, CI 0.079-0.648). One ofthe
patients with a CR died of a biopsy-proven small-cell lung cancer
6 months after CR for oesophageal cancer (squamous cell cancer).
The two patients with PR were still alive at 6 and 14 months from
commencement of treatment. One further patient with metastatic
disease had a tumour regression of > 25% but < 50% of initial
tunour size. The median survival time for all patient in UICC stage
IV was 6 months.
Clinical benefit
Dysphagia, pain and body weight were assessed in the 20 patients
evaluable for response. The overall clinical benefit rate was 70%.
Fifteen patients had dysphagia on study entry, including four who
were swallowing liquids only, nine patients swallowing soft food
only and two symptomatic on regular diet. Five of these patients
obtained complete dysphagia relief and eight a partial remission
with cisplatin/paclitaxel. Weight gain of more than 10% was
observed in one of these patients. One further patient presented
with a strong retrosternal pain. The pain disappeared completely
after the administration offour cycles ofcisplatin/paclitaxel.
DISCUSSION
The prognosis of patients with advanced oesophageal carcinoma
remains extremely poor. The median survival in stage IV disease is
6 months, and so far chemotherapeutic regimens appear to have no
impact on survival (Stahl et al, 1994). Thus, chemotherapy is not
recommended for standard treatment in patients with metastatic
disease.
After surgery for locally advanced oesophageal carcinoma,
recurrence is usually at the primary site or in the regional lymph
nodes. In the majority ofpatients, salvage ofprimary failure is not
feasible. However, for patients with local recurrence, restoration of
the swallowing function and an optimal quality oflife is critical.
In the trial reported here, 65% ofthe patients presented with stage
IV tumours or recurrent disease. An additional seven evaluable
patients had aT4 or aT3/NI cancer, i.e. UICC stage III. Furthermore,
the N-positive patients displayed multiple involved nodal areas on
CT scan or EUS indicating primary unresectability. Thus, only
patients with a very unfavourable prognosis were enrolled.
Cisplatin/5-fluorouracil is considered the standard treatment for
carcinoma of the oesophagus (Ajani et al, 1992; Coia, 1994).
Haematological toxicity of this combination occurred in 34%
(Hilgenberg et al, 1988). Kok et al (1996) encountered severe
leucopenia in 39% ofpatients treated with cisplatin/etoposide, and
severe thrombocytopenia in an additional 24%. Ajani et al (1994)
reported a WHO grade 3/4 granulocytopenia in 86% of their
patients after an infusion of 250 mg m-2 paclitaxel.
In our study, only a mild haematological toxicity was docu-
mented, with 10% of the patients suffering a grade 3 but no grade
4 granulocytopenia. Severe thrombocytopenia was not observed.
The mild toxicity was due to the low doses ofcisplatin (50 mg m-2
cycle-') and paclitaxel (90 mg m-2 cycle-'). Both cisplatin and
paclitaxel are neurotoxic agents, especially in patients with high
alcohol intake. Nevertheless, only one grade 3 - and one grade 4 -
CTC neurotoxicity were observed in this study. With 1 day of
treatment every 14 days, feasible on an outpatient basis, accep-
tance ofthe schedule by the patients was excellent.
With an overall remission rate of 40% in a multicentre setting,
cisplatin/paclitaxel administered every 14 days was effective and
compares with the results of other trials. The combination of 5-
fluorouracil with cisplatin renders a partial and complete response
rate of 55% for patients with local-regional disease, and 30% for
patients with metastatic disease (Ajani, 1994). The remission rates
with cisplatin and etoposide amount to 48% (Kok et al, 1996), and
the combination of 5-fluorouracil, etoposide, folinic acid and
cisplatin induced a response in 45% of patients with stage III and
IV disease (Stahl et al, 1994).
Although toxicity and remission rates were the primary goal of
this study, and clinical benefit ofchemotherapeutic protocols should
be evaluated in randomized trials preferably, we furthermore evalu-
ated the effect ofcisplatin/paclitaxel on symptoms. In this trial, clin-
ical benefit with a complete or partial relief of dysphagia, pain,
and/or a significant weight gain was achieved in 70% ofthepatients.
Spiridonidis et al (I1996) reported that complete dysphagia reliefcan
be observed in patients whose primary oesophageal tumours do not
respond to chemotherapy. The treatment may cause a change in
consistency or appearance of the tumour tissue, thus improving the
patency of the oesophageal lumen. The infusion of cisplatin/pacli-
taxel does not exclude additional supportive measures, such as irra-
diation or laser therapy. However, in order to evaluate the effect of
cisplatin/paclitaxel, these treatment modalities were not applied in
our study. With cisplatin/paclitaxel in the dose and frequency
administered in this study, no major toxicity, but an efficacy within
the region of those occurring with other platinum-containing regi-
mens, was achieved. We have now started a clinical trial with
cisplatin/paclitaxel given in combination with radiotherapy for
locally advanced oesophageal cancer.
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